Is Immunome, Inc. (IMNM) a Buy, Sell, or Hold?
NASDAQ : IMNM
Immunome, Inc.
$22.58 USD
$0.37 (1.67%)
- Volume
- 796.02K
- Average Volume
- 1.36M
- Market Capitalization
- $2.16B
- P/E Ratio
- -9.45
- Dividend Yield
- 0.00%
- Price Target
- $36.50
- Year High
- $27.65
- Year Low
- $8.67
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $21.68
Company Overview
NASDAQ
Clay Siegall
Biotechnology
Healthcare
IMNM
177
US
USD
Liquidity Metrics
0.01
21.68
21.68
21.26
0.00
Sales & Valuation
$6.94M
537.62
4.34
-10.50
-1.82
Profitability
-$2.43
-$212.39M
-5593.85%
-5593.85%
-51.15%
-36.24%
P/E Metrics
-9.45
-0.33
-0.33
Analyst Price Target & Rating
$36.50
$40.00
$33.00
2/5
13 Analysts
-38.14%
Financial Health Scores
39.10
2/9
$566.9M
$619.79M
$31.11M
-$224.59M
Key Metrics (TTM)
$1.54B
384.60
-6.96
21.68
-51.15%
-40.31%
-8.94%
-9.68%
-40 days
Company Executives
| Name | Title |
|---|---|
| Robert J. Lechleider | Chief Medical Officer |
| Max Rosett | Chief Financial Officer |
| Sandra G. Stoneman | Chief Legal Officer, General Counsel & Corporate Secretary |
| Kinney Horn | Chief Business Officer |
| Clay Siegall | Chairman, President & Chief Executive Officer |
| Jack Higgins | Chief Scientific Officer |
| Roee Shahar | Executive Vice President of Commercial |
| Philip Tsai | Chief Technical Officer |
Poll Results
No votes yet today — be the first to share your view!
About Immunome, Inc. (NASDAQ:IMNM) Stock
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington. ...
Atika Capital Management LLC Sells 71,441 Shares of Immunome, Inc. $IMNM
2026-07-24 03:58:28
Atika Capital Management LLC lessened its holdings in Immunome, Inc. (NASDAQ: IMNM) by 21.4% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 262,900 shares of the company's stock after selling 71,441 shares during the quarter. Atika Capital
2026-07-20 07:30:00
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced that the first patient has been dosed in the Phase 1, first-in-human trial of IM-3050, an investigational FAP-targeted radioligand therapy being evaluated in patients with FAP-expressing advanced solid tumors.“FAP is a high-potential target with expression in 75% of solid tumors,” said Bob Lechleider, M.D., Chi.
What This Immunome Sale Means a Day Before a Big FDA Milestone
2026-07-12 16:44:53
An Immunome insider sold 100,000 shares for $2.4 million based on weighted average prices on July 6, 2026 and July 7, 2026. The transaction represents 32% of the insider's total equity holdings in the company.
Immunome Stock Up 32% in a Month: Here's What You Should Know
2026-07-10 11:41:06
IMNM jumps 32% in a month. This comes as the FDA accepts varegacestat's NDA for desmoid tumors, with an approval decision expected by April 2027.
2026-07-08 07:30:00
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced the U.S. Food and Drug Administration (FDA or the Agency) has accepted its New Drug Application (NDA) for varegacestat, an investigational, oral, once-daily gamma secretase inhibitor (GSI), for the treatment of adults with desmoid tumors. The FDA assigned a Prescription Drug User Fee Act (PDUFA) target action.
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-07-07 16:02:00
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on July 1, 2026, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 344,000 shares of common stock to seventeen new employees under the Company's 2024 In.
2026-06-11 08:00:00
[url="]Immunome, Inc.[/url] (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today a
2026-06-11 07:30:00
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced that the first patient has been dosed in the Phase 1, first-in-human trial of IM-1617, a potential first-in-class ADC directed at an undisclosed solid tumor target and incorporating HC74, Immunome's proprietary TOP1 inhibitor payload. “The first patient dosed with IM-1617 is a significant milestone for Immunom.
Frequently Asked Questions
-
What is the current Immunome, Inc. (IMNM) stock price?
-
Immunome, Inc.(NASDAQ:IMNM) stock price is $22.58 in the last trading session. During the trading session, IMNM stock reached the peak price of $27.65 while $8.665 was the lowest point it dropped to. The percentage change in IMNM stock occurred in the recent session was 1.67% while the dollar amount for the price change in IMNM stock was $0.37.
-
IMNM's industry and sector of operation?
-
The NASDAQ listed IMNM is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of IMNM?
-
Robert J. Lechleider | Chief Medical Officer
Max Rosett | Chief Financial Officer
Sandra G. Stoneman | Chief Legal Officer, General Counsel & Corporate Secretary
Kinney Horn | Chief Business Officer
Clay Siegall | Chairman, President & Chief Executive Officer -
How many employees does IMNM have?
-
Number of IMNM employees currently stands at 177. IMNM operates from 18702 North Creek Parkway, Bothell, WA 98011, US.
-
Link for IMNM official website?
-
Official Website of IMNM is: https://www.immunome.com
-
How do I contact IMNM?
-
IMNM could be contacted at phone #610 321 3700 and can also be accessed through its website. IMNM operates from 18702 North Creek Parkway, Bothell, WA 98011, US.
-
How many shares of IMNM are traded daily?
-
The average number of IMNM shares traded daily for last 3 months was 1.36M.
-
What is the market cap of IMNM currently?
-
The market value of IMNM currently stands at $2.16B with its latest stock price at $22.58